In addition, the further GSEA analysis in GBM patients with chemotherapy have found the enrichment of epithelial mesenchymal transition, IL6-JAK-STAT3 pathway and IL2-STAT5 pathway in high-risk group, indicating the important role of immune factors in tumor drug resistance. The gene discussed is IL6; the disease is glioblastoma.